Skip to main content

ADVERTISEMENT

DLBCL

News
12/15/2020
In a study of patients with relapsed/refractory B-Cell NHL, the ViPOR regimen led to complete responses, with no unexpected toxicities.
In a study of patients with relapsed/refractory B-Cell NHL, the ViPOR regimen led to complete responses, with no unexpected toxicities.
In a study of patients with...
12/15/2020
Oncology